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Reprogramming of cellular identity using exogenous
expression of transcription factors (TFs) is a powerful
and exciting tool for tissue engineering, disease
modeling, and regenerativemedicine. However, gen-
eration of desired cell types using this approach is
often plagued by inefficiency, slow conversion, and
an inability to produce mature functional cells. Here,
we show that expression of constitutively active
SMAD2/3 significantly improves the efficiency of
induced pluripotent stem cell (iPSC) generation by
theYamanaka factors.Mechanistically, SMAD3 inter-
acts with reprogramming factors and co-activators
and co-occupies OCT4 target loci during reprogram-
ming. Unexpectedly, active SMAD2/3 also markedly
enhances three other TF-mediated direct reprogram-
ming conversions, from B cells to macrophages,
myoblasts to adipocytes, and human fibroblasts
to neurons, highlighting broad and general roles
for SMAD2/3 as cell-reprogramming potentiators.
Our results suggest that co-expression of active
SMAD2/3 could enhance multiple types of TF-based
cell identity conversion and therefore be a powerful
tool for cellular engineering.
INTRODUCTION
Cell-type-specific transcription factors (TFs), which are respon-
sible for specifying unique cellular identities, are often describedCell Stem Cell 21, 1–15, D
This is an open access article undas master TFs. Those master TFs not only play critical roles in
self-renewal or cell fate specification during normal development
but also can be used to drive cell identity conversions in vitro and
in vivo (Graf, 2011). The first demonstration of cell identity con-
version by an exogenous master TF was in 1987, with overex-
pression of MyoD in fibroblasts resulting in the generation of
myoblasts (Davis et al., 1987). Follow-up studies accomplished
TF-mediated transdifferentiation of hematopoietic lineages (Ku-
lessa et al., 1995; Xie et al., 2004), which led to Takahashi and
Yamanaka (2006) demonstrating the power of this strategy by
generating induced pluripotent stem cells (iPSCs) from differen-
tiated cells with only four TFs (Oct4, Sox2, Klf4, and c-Myc).
Inspired by these seminal works, several different cell types
have been generated by master-TF-mediated cellular identity
conversions (Bussmann et al., 2009; Feng et al., 2008; Kajimura
et al., 2009; Pfisterer et al., 2011; Vierbuchen et al., 2010), hold-
ing tremendous promise for cellular engineering and disease
modeling. While overexpressing cell-type-specific master TFs
is a key concept in forced cell identity conversions, the set of
TFs, culture conditions, functionality of the resulting cells, and
duration of conversion largely vary. Whether common molecular
mechanisms are able to potentiate cell fate conversions across
different models has remained to be explored. It has recently
been demonstrated that CAF-1 is a common roadblock in three
different master-TF-mediated cell conversions (Cheloufi et al.,
2015). Further investigation of reprogramming mechanisms
could unveil common molecular machineries that might similarly
be involved in various cell conversionmodels, ultimately allowing
for more efficient and faithful forced cell identity changes.
Among the several TF-mediated cell conversions, the genera-
tion of iPSCs is one of the most extensively studied systems.
Several smallmolecules, targeting various epigenetic or signaling
pathways, have been identified to enhance the reprogrammingecember 7, 2017 ª 2017 The Authors. Published by Elsevier Inc. 1
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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including transforming growth factor b receptor (TGF-bR) inhibi-
tors (Ichida et al., 2009; Li et al., 2010;Maherali andHochedlinger,
2009). TGF-b signaling counteracts the mesenchymal to epithe-
lial transition (MET) (Xu et al., 2008), an essential early event for
fibroblasts to become iPSCs (Li et al., 2010; Redmer et al.,
2011; Samavarchi-Tehrani et al., 2010), providing a possible
mechanism for how inhibition of this pathway promotes iPSC
generation. However, TGF-bR inhibitors also improve reprog-
ramming efficiency of epithelial cells (Li et al., 2010) and when
added at post-MET stages of the reprogramming process (Ichida
et al., 2009; Li et al., 2010), suggesting additional mechanisms of
the reprogramming enhancement exist.
TGF-bRs transmit signals intracellularly through SMAD2/
3-dependent and independent pathways (Derynck and Zhang,
2003). When phosphorylated by the activated TGF-bRs,
SMAD2/3 translocate to the nucleus with SMAD4 and regulate
transcription of hundreds of genes in a highly context-depen-
dent manner (Massague´, 2012). SMAD2/3 interact with a range
of TFs, as well as transcriptional activators, silencers, and
nucleosome modifiers, including CBP/p300 transcriptional reg-
ulators (Feng et al., 1998), switch/sucrose non-fermentable
(SWI/SNF) chromatin remodelers (Xi et al., 2008), the mixed line-
age leukemia (MLL) histone H3 lysine 4 (H3K4) methyltransfer-
ase complex (Bertero et al., 2015), and the Mediator complex
(Kato et al., 2002). Because SMAD2/3 have weak binding affinity
to DNA (Shi et al., 1998), their robust interaction with the
genome relies on other TFs, which can partially explain cell-
type and context-dependent cellular responses to TGF-b acti-
vation (Derynck and Zhang, 2003; Ikushima and Miyazono,
2010; Massague´ et al., 2005). Recent genome-wide chromatin
immunoprecipitation followed by sequencing (ChIP-seq) ana-
lyses demonstrated that SMAD3 binds almost entirely unique
target loci across the genome in a given cell type, co-localizing
with OCT4, SOX2, and NANOG in embryonic stem cells (ESCs),
PU.1 in pro-B cells, and MYOD1 in myotubes (Mullen et al.,
2011). Thus, SMAD2/3 are powerful gene expression regulators,
yet their potential positive role in iPSC generation has been
disregarded, because the inhibition of the upstream molecule,
TGF-bR, enhances reprogramming efficiency, and because
their involvement in other master-TF-mediated cell identity con-
versions has not been explored.
Here, we demonstrate that TGF-bR inhibitor treatment circum-
vents reprogramming-dependent upregulation of p19ARF, a
senescence inducer, independently of the promotion of the
MET. Unexpectedly, we found that active SMAD2/3 increases
when cells are cultured in the presence of TGF-bR inhibitors
for prolonged periods. Following that observation, we assessed
the impact of constitutively active SMAD2/3 (Smad2/3CA) on
reprogramming and found a remarkable boost in efficiency and
acceleration of the process. However, Cas9-mediated double
knockout of Smad2/3 revealed that endogenous SMAD2/3 was
not responsible for TGF-bR-inhibitor-mediated reprogramming
enhancement, suggesting that other receptor downstream tar-
gets are involved. Irrespectively, we discovered that overex-
pressed SMAD3CA physically interacted with reprogramming
factors and localized at OCT4 target loci during reprogramming.
Moreover, active SMAD3 could also enhance three other
master-TF-mediated cell identity conversions. This work high-2 Cell Stem Cell 21, 1–15, December 7, 2017lights SMAD2/3 as common powerful cofactors that potentiate
diverse forced cell identity conversions with master TFs.
RESULTS
TGF-bR Inhibition Enhances Reprogramming
Independently of the MET
To explore how TGF-bR inhibitors enhance reprogramming
(Ichida et al., 2009; Li et al., 2010; Maherali and Hochedlinger,
2009), we first confirmed the beneficial effect of the ALK4/5/7
inhibitor A83-01 (A83) (Tojo et al., 2005) using mouse embryonic
fibroblasts (MEFs) with doxycycline (dox)-inducible Yamanaka
factors (c-Myc, Klf4, Oct4, and Sox2) and an mOrange
reporter of transgene expression (MKOS-ires-mOrange) (Chant-
zoura et al., 2015). The addition of A83 to reprogramming media
resulted in a 3-fold increase in reprogramming efficiency,
measured by the number of colonies positive for Nanog-GFP
reporter (Figure 1A). TGF-bR inhibitors are thought to facilitate
reprogramming, at least in part, by enhancing the transition to
an epithelial-like state (Li et al., 2010). However, over 70% of
cells demonstrated E-CADHERIN expression after day 4 of
reprogramming either in the presence or absence of A83 in
this reprogramming system with a polycistronic reprogramming
vector containing full-length Klf4, as previously reported (Fig-
ures 1B, S1A, and S1B) (Chantzoura et al., 2015; Kim et al.,
2015; O’Malley et al., 2013). These results suggest that TGF-
bR inhibition facilitates reprogramming independently of the
acquisition of epithelial character in this system. During reprog-
ramming, MKOS-expressing transgenic (Tg; mOrange+) MEFs
were found to proliferate more in the presence of A83, while
the proliferation of surrounding wild-type MEFs was unaffected
(Figure 1C). Real-time PCR and immunofluorescence revealed
that transient upregulation of p19ARF, a p53-dependent cell-
cycle arrest and apoptosis inducer, was suppressed in the Tg
cells on day 4 of reprogramming in the presence of A83 (Figures
1D and 1E). Thus, one of the positive effects of A83 is anti-
senescence/apoptosis at the early stage of reprogramming,
which is consistent with the fact that A83 treatment only at
the initial stages of reprogramming is also beneficial (Figure S1C)
(Maherali and Hochedlinger, 2009). In addition, analysis of re-
programming progression with the cell-surface markers CD44
and ICAM1 indicated that the speed of reprogramming was
also affected by the inhibitor (Figure 1F). MEFs with high
CD44 and broad ICAM1 expression reach an iPSC state by
going through gates 1, 2, and 3, which are marked by CD44
and ICAM1 expression levels (Figure 1F, day 0) (O’Malley
et al., 2013). These CD44 and ICAM1 expression changes
were accelerated in the presence of A83; for example, >50%
of cells had already downregulated CD44 at day 8 as compared
to 15% of control cells (Figure 1F). Moreover, with the addition
of A83, 33.7% of cells were Nanog-GFP+ at day 8, in contrast to
1.6% in the absence of A83, indicating a robust acceleration of
reprogramming. Late reprogramming intermediates generated
in the presence of A83 were 2- to 2.5-fold more likely to
form Nanog-GFP+ colonies when flow-sorted based on CD44/
ICAM1/Nanog-GFP expression profiles at day 10 of reprogram-
ming (Figure S1D). These results confirmed that post-MET
populations are also positively affected by TGF-b inhibition,
underlining the multimodal nature of TGF-b signaling.
Figure 1. Reprogramming Enhancement and Acceleration by TGF-b Inhibitors
(A) Nanog-GFP and GFP+ colony numbers on day 12 of reprogramming.
(B) Flow cytometry analysis of E-CADHERIN (E-CAD) expression during reprogramming.
(C) Numbers of mOrange+ MKOS expressing transgenic (Tg) cells (left) and mOrange wild-type feeder MEFs (right) during the first 4 days.
(D) Real-time RT-PCR for p19Arf with mOrange+ cells on days 4 and 8.
(E) Immunofluorescence for p19ARF on day 4.
(F) CD44/ICAM1/Nanog-GFP expression throughout reprogramming. Red, Nanog-GFP; green, Nanog-GFP+ Tg cells.
Cont and A83 indicate in the absence and presence of A83, respectively. See also Figure S1.
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Successful Reprogramming
Downstream targets of TGF-bRs include SMAD2/3,mitogen acti-
vated protein kinase (MAPK), RhoGTPase, and the phosphatidy-
linositol 3-kinase (PI3K)/AKT pathways (Derynck and Zhang,
2003; Zhang, 2009). TGF-bRs phosphorylate the C terminus of
SMAD3,whichcausescomplex formationwithSMAD4and trans-
location to the nucleus to regulate gene expression (Shi andMas-
sague´, 2003). In the absence of A83 some, but not all, cells in
reprogramming colonies demonstrated phosphorylated SMAD3
(p-SMAD3) at day 4 (Figure 2A, Cont Day4). p-SMAD3 was often
observed in cells with Nanog-GFP expression at day 8 (ContDay8, Figure2A), in contrast today12whenp-SMAD3wasbarely
detectable in Nanog-GFP+ cells (Cont Day 12, Figure 2A). Unex-
pectedly, we observed p-SMAD3+ cells more frequently within
the colonies in the presence of A83 on both day 4 and day 8 of re-
programming (Figure 2A, A83). The finding that p-SMAD3+ cells
increase in the presence of A83 contradicts the knowledge that
ALK4/5/7 inhibitors dampen SMAD3 signaling (Tojo et al., 2005).
However, the increase in p-SMAD3+ cells was also observed at
day 4 of reprogramming with another ALK4/5/7 inhibitor, SB-
431542 (SB43), which likewise enhances reprogramming (Ichida
et al., 2009) (Figure 2B). When we quantified the percentage of
mOrange+ Tg cells with p-SMAD3 foci in the whole-well images,Cell Stem Cell 21, 1–15, December 7, 2017 3
Figure 2. Increased Phosphorylated SMAD3
in the Presence of TGF-b Inhibitors
(A) Immunofluorescence for phosphorylated
SMAD3 (p-SMAD3) on days 4, 8, and 12 of re-
programming in combination with the mOrange
and Nanog-GFP reporters. Scale bar, 100 mm.
(B) Whole-well images of 6-well plates at day 4
of reprogramming. Red, mOrange+ Tg cells; green,
p-SMAD3 staining.
(C) Quantification of cells with strong p-SMAD3 foci
in mOrange+ Tg cells from the day 4 whole-well
images.
(D) Whole-well p-SMAD3 image analysis with wild-
typeMEFs cultured for 1 hrwith no treatment (Cont)
or with the addition of 10 ng/mL TGF-b without
inhibitors () or with A83-01 (A83) or SB431542
(SB43).
(E) p-SMAD2/3 western blotting in wild-type
MEFs treated with 10 ng/mL TGF-b for 1 hr without
inhibitors () or with A83 or SB43.
(F) p-SMAD2/3 western blotting in wild-type MEFs
cultured for 4 days without inhibitors (Cont) or with
A83 or SB43.
(G) Whole-well p-SMAD3 image analysis of wild-
type MEFs cultured for 4 days without inhibitors
(Cont) or with A83 or SB43.
(H) Real-time RT-PCR for TGFbRs and Smad2/3
after 4 days culture ofMEFs in the presence of A83.
Each expression value was normalized to Tbp and
then compared to DMSO-(carrier)-treated control
samples.
All graphs represent averages of 3 independent
experiments, with 2 technical replicates. Error bars
indicate SD. *p < 0.05 based on a two-sided t test.
See also Figure S2.
Please cite this article in press as: Ruetz et al., Constitutively Active SMAD2/3 Are Broad-Scope Potentiators of Transcription-Factor-Mediated Cellular
Reprogramming, Cell Stem Cell (2017), https://doi.org/10.1016/j.stem.2017.10.013therewasa1.5-fold increase in thepresenceof eitherA83orSB43
(Figures 2C andS2A). Notably, both the image analysis andwest-
ern blotting demonstrated that either A83 or SB43 could block
SMAD2/3 phosphorylation in MEFs treated with TGF-b for 1 hr
(Figures 2D, 2E, and S2B). These data demonstrate that these
inhibitors can work as predicted for short-duration treatments.
However, when wild-type MEFs were cultured in the presence
of inhibitors for 4 days, we observed a clear increase in
p-SMAD2/3 levels (Figures 2F, 2G, and S2C) similar to that
observed in Tg cells during reprogramming (Figures 2A–2C).
Many TGF-bR (Alk1, Alk4, Alk7, Tgfbr2, and Tgfbr3) were upregu-
lated in MEFs after 4 days-treatment with A83 (Figure 2H). This
may be a feedback mechanism that contributes to the unex-
pected cellular response of increased p-SMAD2/3 levels during
prolonged exposure to TGF-bR inhibitors.
Constitutively Active SMAD2/3 Boost Reprogramming
It was previously shown that SMAD3 is recruited to target loci by
cell-type-specific master TFs, including by OCT4 to pluripotency
gene loci in mouse ESCs (Mullen et al., 2011). Furthermore,
SMAD3 interacts with several TFs, chromatin remodelers, and
transcriptional regulators in a number of diverse cell types (Gaar-
enstroom and Hill, 2014). Our observations that the majority
of cells becoming Nanog-GFP+ are p-SMAD3+ (Figure 2A) and
prolonged treatment of cells with TGF-bR inhibitors increased4 Cell Stem Cell 21, 1–15, December 7, 2017the number of p-SMAD3+ cells (Figures 2B–2G) prompted
us to investigate roles for SMAD3 during reprogramming. We
first tested whether constitutively active forms of SMAD2
(SMAD2CA) or SMAD3 (SMAD3CA) (Chipuk et al., 2002; Funaba
and Mathews, 2000) could boost reprogramming. Interestingly,
retroviral overexpression of Smad2CA and/or Smad3CA in our
MKOS reprogramming system resulted in an over 6-fold in-
crease in Nanog-GFP+ colonies, and the combined effect of
Smad2CA and 3CA resulted in a 10-fold increase in efficiency
(Figures 3A and S3A). Flow cytometry analysis revealed that
expression changes of CD44, ICAM1, and Nanog-GFP were
accelerated in the presence of Smad3CA, while E-CAD expres-
sion was not affected (Figures 3B–3D). Analyses of other reprog-
ramming cell surface markers including MEFSK4, CD47, CD73
and CD104 (Lujan et al., 2015) also demonstrated accelerated
reprogramming phenotypes at later time points beyond day 6
(Figure S3B). Smad3CA did not enhance the proliferation
of cells undergoing reprogramming at the early stages (Fig-
ure 3E), different from A83 treatment (Figure 1C). When directly
compared, reprogramming efficiency with A83 was higher than
that of Smad3CA overexpression, and treatment with A83 and
Smad3CA together did not further improve reprogramming effi-
ciency (Figures 3F and S3C). The strong effect of A83, including
its anti-senescence action, is potentially masking the effect of
Smad3CA and/or their downstream mechanisms of facilitating
Figure 3. Constitutively Active Smad2/3 Boosts Reprogramming
(A) Nanog-GFP+ colony numbers on day 15 of reprogramming with retroviral infection of control vector (Cont), constitutive active Smad2 (+Sm2CA), Smad3
(+Sm3CA), or Smad2CA plus Smad3CA (+Sm2CA+Sm3CA).
(B) CD44/ICAM1/Nanog-GFP expression during reprogramming with control (top) and Smad3CA (bottom) expression vector infection. Red,Nanog-GFP; green,
Nanog-GFP+ Tg cells.
(C and D) E-CAD (C) and Nanog-GFP (D) expression during reprogramming with control, Smad2CA, Smad3CA, or Smad2CA plus Smad3CA expression vector
infection.
(E) Numbers of Tg (left) and wild-type feeder MEFs (right) with control (Cont) or Sm3CA vectors during reprogramming.
(F) Nanog-GFP+ colony numbers on day 15 of reprogramming in the presence of A83, Sm3CA, or A83 plus Sm3CA.
(legend continued on next page)
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reprogramming enhancement is attributed to the unexpected
increase of p-SMAD2/3, we performed reprogramming after
knocking out both Smad2 and Smad3 in dox-inducible MKOS
MEFs with constitutive Cas9 expression by infection of lentiviral
guide RNA (gRNA) expression vectors (Figure S3D) (Tzelepis
et al., 2016). Efficient double knockout (KO) was confirmed by
western blotting 3 days after gRNA vector infection (Figure 3G).
Unexpectedly, Smad2/3 double KO did not have obvious effects
on reprogramming efficiency in either the presence or absence
of A83 (Figures 3H and 3I). This indicated that reprogramming
enhancement by A83 was largely SMAD2/3 independent and
that endogenous SMAD2/3 is not required for mouse iPSC gen-
eration. Nevertheless, SMAD2/3CA also enhanced the genera-
tion of human iPSCs within an episomal reprogramming system
(Okita et al., 2011) (Figure S3E). Independently, Yamakawa et al.
(2016) also identified SMAD2 as one factor that can enhance hu-
man iPSC generation in a cDNA overexpression screen. These
results solidified the notion that exogenous SMAD2/3 facilitates
reprogramming and warranted further mechanistic analysis.
Accelerated Reprogramming Process by Smad3CA
First, we performed time-course global gene expression profiling.
Day 15 Nanog-GFP+ cells generated from reprogramming with
the addition of Smad3CAwere similar to ESCs (R2 = 0.968), indi-
cating that Smad3CA expression does not alter the final outcome
of reprogramming (Figure S4A). When we compared samples
on days 3, 6, 8, and 10 of reprogramming with and without
Smad3CA expression, higher Smad3 expression was clearly
detectable in +Smad3CA samples, especially at earlier time
points before viral vector silencing occurs (Figure 4A, red trian-
gles). Unexpectedly, global gene expression was very similar be-
tween control and +Smad3CA samples across these time points
(Figure 4A, gray dots). However, expression of almost all pluripo-
tency-associated genes became higher in +Smad3CA samples
by day 10, as further illustrated by gene set enrichment analysis
(GSEA) (Figures 4A, 4B, and S4B; all read counts are available
in Table S1) (Subramanian et al., 2005). Similarly, when we inves-
tigated expression patterns of genes >4-fold up- or downregu-
lated in ESCs compared to MEFs (438 and 815 genes, respec-
tively) during reprogramming, a small but global acceleration
of up- and downregulation by Smad3CA was apparent (Figures
4C–4E). These results indicated that SMAD3CA expression
did not cause outstanding gene expression changes compared
to those induced by Yamanaka factors alone but globally
boosted the required gene expression changes, resulting in a
clear enhancement of reprogramming.
To further investigate how SMAD3CA altered the gene expres-
sion changes caused by Yamanaka factors, we first performed
pattern clustering with control and +Smad3CA samples (Fig-
ure S4C). We classified 3,750 genes with above-background(G) Efficient double knockout (dKO) of Smad2 and Smad3 was observed 72 hr a
(Smad2g2+Smad3g1, Smad2g4+Smad3g5). Controls included samples with
(Pecam1g1) and Icam1 (Icam1g1), respectively.
(H and I) Smad2/3 double KO did not affect reprogramming efficiency in the prese
were used as negative and positive controls, respectively.
Graphs represent averages of 3 (A, C, D–F, F) or 2 (I) independent experiments w
(two-sided t test). See also Figure S3.
6 Cell Stem Cell 21, 1–15, December 7, 2017expression levels (mean countR2) and high variation (coefficient
of variation >100) into 8 distinct gene expression patterns (scaled
expression profiles are shown in Figure S4C, and classification of
genes is available in Table S1), of which 7 cluster patterns in con-
trol and +Smad3CA sample series were very similar: downregu-
lated by day 3 (Dwn), transiently upregulated at day 3 (D3Up),
transiently upregulated at day 8 (D8Up), highly (D10Up) or slightly
(D10sUp) upregulated at day 10 but low expression in ESCs, ex-
pected to be upregulated after day 10 (Up), and finally a down
and up cluster (DwnUp). Additionally, the control series had a
cluster of transiently upregulated genes on day 6 (D6Up), and
the +Smad3CA series had a group of genes upregulated
earlier than the Up genes (eUp). A comparison of the genes
classified in each category revealed that genes in Dwn, D3Up,
Up, and DwnUp clusters were very similar between control
and+Smad3CA samples as shownwith pale colors in the corddi-
agram (Figure S4D). Most of the genes in other categories were
cross-classified between the control and +Smad3CA series.
Among the cross-classified gene groups, 5 had over 100 genes
(FigureS4D, *E-I).Most of the control D8Upgeneswereclassified
into +Smad3CA D10sUp genes (108 genes), with their upregula-
tionminimized in the presence of +Smad3CAwhenmedians of all
the 108 genes from the control (blue) and +Smad3CA (red) series
were plotted along the time points (Figure S4E). These 108 genes
were enriched in nervous-system-related genes, potentially indi-
cating unnecessary upregulation of SOX2 targets reflecting its
critical roles in neurons (Figure S4J). Approximately 24% and
45% of control D10Up genes were cross classified into D8Up
(124 genes) or D10sUp (233 genes) +Smad3CA clusters,
where the peak of the transient upregulations of the median line
in +Smad3CA occurred earlier at day 8 (Figure S4F) or was mini-
mized (Figure S4G), respectively. These two groups of genes
were enriched in immune-response-associated genes (Fig-
ure S4J). Most of the control D10sUp genes fell into +Smad3CA
D10Up cluster (102 genes), but those had relatively low upregu-
lation in the +Smad3CA series (compare +Sm3CA [red] median
line in Figure S4H with the Cont [blue] median lines in Figures
S4F and S4G). Finally, almost all genes that belonged to eUp, a
unique cluster in the +Smad3CA series, were classified in the
control Up cluster (120 genes) (Figure S4I), indicating an acceler-
ated upregulation for these genes. Altogether, these gene
expression cluster analyses suggested a global and swifter tran-
sition to a pluripotent state with less transient upregulation of
miscellaneous genes and/or less production of divergent cells
that are unable to become iPSCs in the presence of Smad3CA.
SMAD3 Interacts with Both Nucleosome Remodelers
and Reprogramming Factors and Co-occupies OCT4
Targets throughout the Genome
SMAD3 is ubiquitously expressed and interacts with many
different proteins, including TFs and co-activators, in variousfter co-infection of lentiviruses encoding gRNA targeting Smad2 and Smad3
no gRNA infection and with co-infection of gRNA viruses against Pecam1
nce or absence of A83. Pecam1g1+Icam1g1 and Stat3g1 (gRNA against Stat3)
ith 2 technical replicates. Error bars indicate SD. *p < 0.05; NS, not significant
Figure 4. Accelerated Global Gene Expression Changes toward iPSCs by Smad3CA
(A) Global gene expression comparison between reprogramming with control (Cont) and +Smad3CA (+Sm3CA) vector expression on days 3, 6, 8, and 10. The
diagonal dashed lines represent 2-fold differences.
(B) Gene set enrichment analysis (GSEA) for the pluripotency genes highlighted in (A). ES, enrichment score.
(C) Genes >4-fold up- and downregulated in ESCs compared to MEFs. Solid and dotted diagonal lines represent 1-fold and 4-fold changes, respectively. The
x and y axes show log2 read counts.
(legend continued on next page)
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weak compared to other TFs, to the extent that its interaction
with other TFs determines where SMAD3 binds throughout the
genome (Massague´ et al., 2005; Mullen et al., 2011; Shi et al.,
1998). We therefore hypothesized that SMAD3, in combination
with nucleosome remodelers or co-activators, is recruited by
OCT4, SOX2, and/or KLF4 to their binding sites, which augments
expression of target genes during reprogramming. Indeed,
SMAD3 immunoprecipitation pulled down OCT4, SOX2, and
KLF4 (mildly) at day 4 of reprogramming when expressing
Smad3CA (Figure 5A). We could also detect interactions be-
tween SMAD3 and histone modifiers and transcriptional regula-
tors, including DPY30 (part of the MLL complex), p300, and
BRG1 (part of the SWI/SNF complex), but not MED15 (part of
the Mediator complex) (Figure 5A). To investigate the possibility
that SMAD3 bridges reprogramming factors with co-activators,
we assessed interactions between OCT4 and the co-activators
at day 4 of reprogramming in the presence or absence of
Smad3CA. Interaction between OCT4 and DPY30 (MLL com-
plex), but not p300, was readily detectable at day 4 of reprog-
ramming in the control conditions (Figure 5B). However, when
SMAD3CA was overexpressed, the amount of DPY30 pulled
down with OCT4 increased nearly 3-fold (Figures 5B and 5C),
indicating that SMAD3CA facilitated the interaction between
OCT4 and the MLL complex component. Furthermore, ChIP-
seq analysis revealed that just 3 days of MKOS induction largely
altered SMAD3-binding sites across the genome, yielding 1,176
novel binding sites and losing the 904 binding sites observed in
the starting MEF population (false discovery rate [FDR] < 0.1)
(Figure 5D). The Oct4-binding sites on day 3 of reprogramming
were clearly co-occupied by SMAD3, while SMAD3 binding
was hardly detectable in the absence of Yamanaka factor
expression at those loci, suggesting a recruitment of SMAD3
byMKOS (Figures 5E and 5F). Chromatin at those OCT4-binding
loci was closed in MEFs, but open on day 3 of reprogramming
either in the presence or absence of exogenous Smad3CA (Fig-
ures 5E and 5F), confirming OCT4 as a pioneering factor (Soufi
et al., 2012).We then performed an assay for transposase acces-
sible chromatin with high-throughput sequencing (ATAC-seq),
which demonstrated that chromatin at early OCT4-binding loci
was similarly accessible regardless of either the presence or
absence of SMAD3CA co-expression on day 3 (Figures 5E and
5F). It has been reported that histone marks of OCT4 target
loci dynamically change during reprogramming (Chronis et al.,
2017). Considering the ability of SMAD3 to interact with histone
modifiers, such as Dpy30 and p300 (Figure 5A), SMAD3CAmight
contribute to such changes and facilitate gene expression
changes toward iPSCs. In fact, we could detect increased
H3K4me3 at promoters of 5 out of 6 pluripotency genes (Fig-
ure 5H, red), near which SMAD3 binding was observed on
day 8 of reprogramming (blue, Figure 5G), although it could be
either a cause or a consequence of enhanced reprogramming
by SMAD3CA. In summary, these results support a model(D) Read count ratios (+Sm3CA/Cont) of all 18,909 genes, 438 ESC upregulated ge
boxplots. Red crosses represent mean.
(E) Scatterplots (+Sm3CA versus Cont) of ESC up- and downregulated genes in (C
respectively.
See also Figure S4 and Table S1.
8 Cell Stem Cell 21, 1–15, December 7, 2017whereby Smad3 interacts with reprogramming factors and is
directed to their target loci, which potentially facilitates the
recruitment of histonemodifiers and/or nucleosome remodelers,
facilitating the cell identity change.
Smad3CA Potentiates Other Master-TF-Mediated Cell
Identity Conversions
Before and after the initial generation of iPSCs in 2006, several
cell types have been generated by overexpression of cell-type-
specific master TFs (Bussmann et al., 2009; Davis et al., 1987;
Feng et al., 2008; Kajimura et al., 2009; Pfisterer et al., 2011; Vier-
buchen et al., 2010; Xie et al., 2004). SMAD3 is known to interact
with a multitude of cell-type-specific master TFs (Massague´,
2012; Mullen et al., 2011). We asked whether Smad2/3CA
could boost other master-TF-mediated cell identity conversions.
B cells can be converted to macrophages by overexpression of
Cebpa (Bussmann et al., 2009; Fukuchi et al., 2006; Xie et al.,
2004) (Figure 6A). The conversion is near 100% efficient, occur-
ring over a 6-day period, and can be monitored by downregula-
tion of the B cell surface marker CD19 and upregulation of the
macrophage marker MAC-1. Expression of Smad2/3CA hardly
affected CD19 downregulation; however, more than 75% of
cells became MAC-1+ by day 4 of conversion with Smad2/3CA
compared to less than 30% of cells converted with Cebpa alone
(Figures 6B and 6C). Furthermore, in the Smad2/3CA expressing
samples, cells with very high granularity, a feature of mature
myeloid cells, could be observed from day 3 (Figure 6D). Quan-
titative PCR (qPCR) detected accelerated upregulation of the
macrophage markers Mac1, Csfr, and Fcgr1 and downregula-
tion of the pre-B cellmarkersRag1,Pax5, andVpreb2 (Figure 6E).
By analyzing CEBPa ChIP-seq data 18 hr after initiation of the
B cell to macrophage conversion, we also found that 1,255
out of 4,211 CEBPa-binding peaks had SMAD-binding motifs
(Figures S5A and S5B) (Di Stefano et al., 2016). Genes associ-
ated with those peaks were highly enriched in gene ontology
terms related to macrophage functions (Figure S5C). ChIP-
qPCR confirmed that SMAD3 indeed bound to these loci during
the B cell to macrophage conversion (Figures S5D and S5E). In
summary, SMAD2/3CA significantly accelerated and enhanced
the CEBPa-mediated B cell to macrophage conversion, likely
via its recruitment to CEBPa targets.
Next, we investigated the process of converting myoblasts
to adipocytes with Cebpb and Prdm16 (Kajimura et al., 2009)
(Figure 6F). Successful conversion of C2C12 myoblasts to
adipocytes can be assessed by oil red O staining, which iden-
tifies the triglycerides and lipids in converted adipocytes.
Expression of either Smad2CA or Smad3CA in conjunction
withCebpb andPrdm16 resulted in an20% increase in conver-
sion efficiency (Figures 6G and 6H).
Finally, we addressed whether Smad2/3CA can accelerate
conversion of human fibroblasts to neurons by Ascl1,Brn2a,My-
tIl, and NeuroD1 (ABMN) (Figure 7A) (Pang et al., 2011). The pro-
portion of cells with neuronal morphology and expressing thenes, and 815 ESC downregulated genes at days 3, 6, 8, and 10 are shown with
) and (D). Solid and dotted diagonal lines represent 1-fold and 2-fold changes,
Figure 5. SMAD3 Interacts with Reprogramming Factors and Chromatin Remodelers and Is Localized at OCT4-Binding Sites during
Reprogramming
(A) Co-immunoprecipitation (co-IP) of SMAD3 and reprogramming factors or chromatin remodelers at day 4 of reprogramming with Smad3CA expression.
Nucl ex, 10% of nuclear extract used for co-IP; IgG, immunoglobulin G (negative control for co-IP).
(B) Co-IP of OCT4 and DPY30 at day 4 of reprogramming with control (Cont) or Smad3CA (+Sm3CA) vector expression. An interaction between OCT4 and P300
was not observed.
(C) DPY30 band intensity analysis from 2 independent experiments shown in (B).
(D) Comparison of SMAD3-binding peaks in MEFs with overexpression of Sm3CA or Sm3CA plus Yamanaka factors for 3 days.
(E and F) OCT4, SMAD3 ChIP-seq, and ATAC-seq heatmaps at OCT4 bound loci (E) and tracks at the Tet2 and Gdf3 loci (F) with (+) and without () MKOS
induction in the presence (+) or absence of () Sm3CA expression for 3 days.
(G) SMAD3 ChIP-qPCR at day 8 of reprogramming with Smad3CA expression at known Oct4-binding loci in ESCs associated with pluripotency genes. Fold
enrichment refers to enrichment over the averaged value of binding to known unbound regions of the Oct4 and Nanog genes.
(H) H3K4me3 ChIP-qPCR at day 8 of reprogramming with control (Cont) and Smad3CA (+Sm3CA) vector expression. Data are shown as relative enrichment
in +Sm3CA samples against control samples.
Graphsrepresentaveragesof2 (H3K4ChIP) or3 (Smad3ChIP) independentexperimentswith2 technical replicates.Errorbars indicateSD. *p<0.05 (one-sided t test).
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Figure 6. Smad2/3CA Potentiate Macrophage and Adipocyte Conversions
(A) Conversion of B cells to macrophages by retroviral transduction of Cebpa with or without Smad2CA (Sm2CA) or Smad3CA (Sm3CA).
(B) Expression changes of the B cell marker CD19 and the macrophage marker MAC-1 during the Cebpa-mediated transdifferentiation process with additional
control (Cont), Sm2CA, or Sm3CA vector expression.
(C) Quantification of CD19 and MAC-1 expression.
(D) Changes in forward scatter (FSC) and side scatter (SSC).
(legend continued on next page)
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pression of Smad2/3CA, as assessed at day 7, 12, or 20 after
initiation of ABMN transgene expression (Figures 7B and 7C).
However, we could observe a clear interaction between
SMAD3 and one of the induced neuron (iN) factors, BRN2 (Fig-
ure 7D), and when we assessed neuronal maturity by patch-
clamp electrophysiology, marked differences emerged (Fig-
ure 7E). On days 23–25 of the neural conversion, 25% (3/12) of
human iNs (hiNs) generated with ABMN showed only immature
single action potentials (APs) after step-wise current injections,
and 75% (9/12) were not functional at this time point (Figure 7E,
Cont). In contrast, with the addition of Smad2CA or Smad3CA,
44% (4/9) or 40% (6/15) of hiNs had single APs, and 33% (3/9)
or 26.7% (4/15) showed amoremature phenotypewith repetitive
APs, respectively, which was consistent with their significantly
greater membrane capacitance and Na+, K+ currents (Figures
7E, S6A, and S6B). To reveal molecular signatures that explain
this accelerated maturation, we performed RNA sequencing
(RNA-seq) analysis. To our surprise, gene expression was very
similar on day 23, with only 5 differentially expressed genes
(USH1C, C12orf29, KIAA0391, SEZ6, and COMMD8 with fold
change [Fc] >2, FDR <0.1) between control and +Smad3CA
iNs (Figure 7F; all reads counts are available in Table S2). There
was also no difference in expression of glutamatergic- and
GABAergic-neuron-associated genes, which are themain neural
subtypes generated by ABMN (Figure S6C) (Pang et al., 2011;
Vierbuchen et al., 2010). However, earlier phenotypes were
evident in 294 and 309 genes up- and downregulated, respec-
tively, on day 12 in iNs generated with Smad3CA (Figure 7G;
Fc >2, FDR <0.1). The most enriched gene ontology (GO)
terms in the upregulated genes were ‘‘nucleobase-containing
compound transport,’’ ‘‘ectoderm development,’’ and ‘‘nervous
system development’’ genes (Figure 7H). Intriguingly, many of
those genes are further upregulated on day 23 in both control
and +Smad3CA (Figure 7H, pale blue and pink). Thus, we
hypothesized that SMAD3CA expression accelerated gene
expression changes caused by ABMN in a global manner, similar
to what was observed in iPSC generation, and resulted in faster
neural maturation. To test this hypothesis, we generated a list of
differentially expressed genes between day 12 and day 23 con-
trol samples and identified 634 up- and 347 downregulated
genes at day 23 (>3-fold, FDR <0.1) (Figure 7I). The most en-
riched GO terms in these upregulated genes were ‘‘cell commu-
nication,’’ ‘‘biological adhesion,’’ ‘‘ectoderm development,’’ and
‘‘nervous system development’’ (Figure 7J). Strikingly, the
majority of the 634 late iN upregulated genes were more highly
expressed in +Smad3CA iNs on day 12 (Figure 7K). Global, faster
downregulation of the late iN downregulated genes was also
evident in day 12 +Smad3CA iNs, including multiple ‘‘metabolic
process’’-related genes (Figure 7L). These results revealed that(E) qPCR analysis of macrophage and pre-B cell markers.
Graphs in (C) and (E) represent averages of 2 independent experiments with 2 te
t test).
(F) Conversion of C2C12 myoblasts to adipocytes with expression of Cebpb and
(G) Oil red O staining of cells 6 days post induction of Cebpb and Prdm16 with a
(H) Quantification of oil red O staining. Graphs represent averages of 2 independe
G. **p < 0.01; *p < 0.05 (two-sided t test).
See also Figure S5.when co-expressed with neural master TFs, SMAD3CA could
remarkably accelerate global gene expression changes, result-
ing in faster iN maturation and formation of neural connectivity
as revealed by patch-clamp recordings.
In summary, in addition to iPSC generation with Yamanaka
factors, SMAD2/3CA potentiated three other master-TF-medi-
ated cell identity conversions, showing that SMAD2/3 are part-
ners of multiple TFs and chromatin modifiers in various contexts.
DISCUSSION
Cell identity conversions by the exogenous expression of
master TFs offer powerful tools for tissue engineering, disease
modeling, and regenerative medicine, yet a deeper understand-
ing of the underlying molecular mechanisms is necessary
to make such extraordinary processes more efficient and
prompt. This study identified that exogenous, constitutive active
SMAD2/3 can act as a part of the core cellular machinery
that potentiates forced cell identity changes with master TFs.
Mechanistically, during iPSC generation, SMAD3 co-occupied
OCT4-binding sites across the genome and facilitated cellular
conversion, likely providing a platform to recruit chromatin
remodelers and transcriptional activators.
Our study commenced with the investigation of how TGF-bR
inhibitors enhance reprogramming efficiency. One of the mech-
anisms involved suppression of p19ARF upregulation. While we
observed that prolonged TGF-bR inhibitor treatment unexpect-
edly increased p-SMAD2/3 levels, double KO of endogenous
Smad2/3 did not affect reprogramming efficiency in the pres-
ence or absence of A83, indicating that the positive effects of
A83 are likely independent of SMAD2/3. However, overexpres-
sion of constitutively active SMAD2/3 boosted iPSC generation
through recruitment to Oct4 target loci and markedly enhanced
three other master-TF-mediated cell conversions.
In addition to widely expressed co-activators and co-
repressors, a multitude of cell-type-specific TFs interact with
SMAD2/3 (Massague´ et al., 2005), partially explaining cell-
type-dependent responses to TGF-b signaling (Mullen et al.,
2011). During cell fate specification, it is thought that TFs might
compete to recruit active SMAD2/3-co-activator complexes to
target loci and activate their targets (Massague´, 2012; Mullen
et al., 2011). Analogously, the amount of active SMAD2/3 could
be a rate-limiting factor to fully realize the exogenous TF’s poten-
tial during forced cell identity changes, resulting in inefficient and
incomplete cellular conversion, even when the best possible
combinations of master TFs are used. In such cases, SMAD2/
3CA overexpression might overcome these limitations and
enhance cell conversions.
The rapid and efficient generation of functionally mature adult
cell types represents a major challenge in the direct cellularchnical replicates, respectively. *p < 0.05; **p < 0.01; ***p < 0.001 (two-sided
Prdm16 with or without Sm2CA or Sm3CA.
n additional control (Cont), Sm2CA, or Sm3CA vector.
nt experiments, with 3 technical replicates, one of those images is presented in
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Figure 7. Smad3CA Accelerates the Generation of Mature iNs
(A) Conversion of human fibroblasts to iNs by lentiviral transduction of Ascl1, Brn2a, Myt1L, and NeuroD1 (ABMN) with or without Smad2CA (Smad2CA) or
Smad3CA (Sm3CA).
(legend continued on next page)
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the protocols used to generate fully functional human neurons,
whether derived from ESCs or by direct conversion of differenti-
ated cells, require months (Brennand et al., 2011; Kriks et al.,
2011; Pereira et al., 2014). The use of SMAD2/3CA in the gener-
ation of mature neurons and potentially other challenging cell
types represents an exciting opportunity for disease modeling
and regenerative medicine. Various cell types share multiple
TFs, co-activators, and co-repressors, and they contribute to
the establishment of unique cellular character during normal
development. Our findings propose that other shared co-factors
could also be powerful tools to achieve more efficient and
precise cell conversions.STAR+METHODS
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
All animal experiments for the iPSC generation were approved by the University of Edinburgh Animal Welfare and Ethical Review
Body, performed at the University of Edinburgh, and carried out according to regulations specified by the Home Office and Project
License. All experiments for the B-to-M conversion were approved by the Ethics Committee of the Barcelona Biomedical Research
Park (PRBB) and performed according to Spanish and European legislation. The use of human fetal fibroblasts is in compliance with
Lund University ethical guidelines and practices.
Primary cell lines
The TNGMKOS reprogramming line harbors a targetedNanog-GFP (TNG) reporter at the AUG start site of exon 1 of theNanog locus,
thereby creating a reporter of the endogenous promoter activity, while also producing a heterozygous KO of the targeted allele
(Chambers et al., 2007). The TNG line was targeted with an MKOS-ires-mOrange dox inducible reprogramming cassette that also
harbored a CAG promoter driven rtTA, targeted to the Sp3 locus (Chantzoura et al., 2015). The resulting TNG MKOS ESC lineCell Stem Cell 21, 1–15.e1–e9, December 7, 2017 e2
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Reprogramming, Cell Stem Cell (2017), https://doi.org/10.1016/j.stem.2017.10.013was used to generate TNGMKOSMEFs from E12.5 chimeric embryos (mixture of male and female embryos) via morula aggregation,
and a reprogrammable TNG MKOS mouse line via blastocyst injection. Percentages of Tg MEFs from each chimeric embryo were
assessed bymOrange expression after culturing a small portion of theMEFs in the presence of 1 mg/ml doxycycline (dox) for 48 hours
before freezing down the rest of the MEFs. The TNG MKOS mouse line was backcrossed with CD1 mice 3-6 generations before
used to generate TNG MKOS MEFs from mixture of male and female E12.5 embryos.
MEFs were cultured at 37C, 5% CO2 in MEF medium (Glasgow’s Minimum Essential Medium (GMEM), 10% FCS, non-essential
amino acids, 2 mM L-Glutamine, 1 mM sodium pyruvate, 100 U/ml penicillin/streptomycin, all from Life technologies) supplemented
with 5 ng/ml FGF2 (Peptrotech) and 1 ng/ml heparin (Sigma-Aldrich). The TNG MKOS ESC line was maintained on gelatin in ESC
medium (MEF medium without FGF2 and heparin, supplemented with human LIF 100 U/ml).
Pre-B cells (a mixture of both male and female) were isolated from bone marrow of inducible CebpaER mice (Fukuchi et al., 2006)
using monoclonal antibodies to CD19 (1D3, BD Pharmigen), using MACS (Miltenyi Biotech).
C2C12 cells (female) were obtained from ATCC and cultured in DMEM supplemented with 10% FBS, L-glutamine and penicillin/
streptomycin (Life Technologies).
Human (female) fetal lung (hFL1, ATCC- CCL- 153) fibroblasts were cultured in ATCC-formulated F-12K Medium, supplemented
with 10% fetal bovine serum at 37C, 5% CO2.
METHOD DETAILS
MEF Reprogramming
Reprogramming was performed on gelatin-coated plates with ESCmedium containing doxycycline (dox) (300 ng/ml, Sigma-Aldrich),
10 mg/ml Vitamin C (Sigma-Aldrich), with or without 500 nM A83-01 (A83) (Tocris, #2939) or 10 mMSB431542 (SB43) (Tocris, #1614,).
Reprogramming experiments, except immunoprecipitation and ChIP, utilized a mixture of Tg MEF harvested from E12.5 chimeric
embryos generated by morula aggregation as described above (5%) and wild-type MEFs (95%) in order to avoid saturating the
number of iPSC colonies in the assays. MEFs were defrosted at high confluence (> 70%) in MEF media 2-3 days prior to plating
for reprogramming. One day prior to initiating reprogramming, the cells were seeded on gelatin pre-coated plates at 1x105 total cells
for 1 well of a 6-well plate, or 7x105 total cells for a 10cm plate, which is 5x103 or 3.6x104 Tg cells, respectively. One day after plating,
MEFmedia is replacedwith reprogrammingmedia containing 300 ng/ml dox to activate expression ofMKOS reprogramming factors.
Reprogramming media is replenished every 2 days until the end of the experiment.
For immunoprecipitation and ChIP, which required a large amount of cells undergoing reprogramming, we used Tg MEFs derived
from a TNGMKOSmouse line (Nanog+/GFP and Sp3+/tetO-MKOS-ires-mOrange, CAG-rtTA) with 129 and CD1mixed genetic background and
perform the experiments with 100% Tg cells with 5x104/well (6 well plate) or 5x105 cells/10 cm dish.
B cell to macrophage transdifferentiation
Pre-B cells were isolated from bone marrow of inducible CebpaER mice (Fukuchi et al., 2006) using monoclonal antibodies to CD19
(1D3, BD Pharmigen), using MACS (Miltenyi Biotech). After infection with Smad3CA or control retroviral vectors, pre-B cells were
plated on S17 feeder cells in RPMI medium supplemented with 10% FBS (Life technologies), 10 ng/mL IL-7 (Peprotech). Transdiffer-
entiation was induced by treating the cells with 1 mM 4-OHT (Sigma), supplemented with 10 ng/mL of IL-7 (Peprotech), IL-3
(Peprotech), human colony-stimulating factor 1 (hCSF-1), FLT3 ligand (Peprotech) and stem cell factor (SCF). Cells stained with
antibodies against MAC-1 (44, BD Pharmigen) and CD19 (1D3, BD Pharmigen) were analyzed with a FACS LSR fortessa flow cytom-
eter (BD Biosciences) and FlowJo software (Tree Star, V10). S17 feeder cells were maintained in DMEM supplemented with 10%
FBS, L-glutamine and penicillin/streptomycin (Life Technologies).
Myoblast to adipocyte transdifferentiation
C2C12 cells were obtained fromATCC and cultured in DMEM supplementedwith 10%FBS, L- glutamine and penicillin/streptomycin
(Life Technologies). C2C12 were infected with Cebpb, Prdm16 and either Smad3CA or control retroviral vectors for 48 hours. After
the infection, cells were cultured in adipogenic-induction medium (DMEM containing 10% FBS, 0.5 mM isobutylmethylxanthine,
125 nM indomethacin, 5M dexamethasone, 850 nM insulin, 1 nM T3 and 1 M rosiglitazone (Santa Cruz) for 2 days. Subsequently,
medium was switched to DMEM containing 10% FBS, 850 nM insulin, 1 nM T3 and 1 mM rosiglitazone, and cells were maintained
for 4 days in this culture condition before Red Oil O staining was performed. All the reagents were purchased from Sigma unless
otherwise indicated. For Oil Red O staining, cultured cells were washed with PBS and fixed in formalin for 10 min at room temper-
ature. Cells were incubated for 30 min at room temperature with 60% filtered Oil Red O stock solution (0.3 g/100 mL of isopropanol)
(Sigma). Cells were washed with 60% isopropanol and then water before visualization. Lipid levels were quantified by extracting Oil
Red O stained cells with isopropanol and measuring absorbance at 510 nm.
Generation of human iNs
Human fetal lung (hFL1, ATCC- CCL- 153) fibroblasts were purchased from the American Type Culture Collection (ATCC) and were
expanded in MEF medium and grown at 37C in 5% CO2. hFL1 were converted to hiNs by transduction of the cells with lentiviral
vectors (LVs) encoding for the conversion factors Ascl1, Brn2a, Myt1L, NeuroD1 with or without Smad3CA (MOI = 5) and co- trans-
duction of the transactivator (FUW-rtTA-SM2, Addgene) (MOI = 10). Transgene expression was initiated by doxycycline (2 mg/ mL,e3 Cell Stem Cell 21, 1–15.e1–e9, December 7, 2017
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dium (N2B27 + doxycycline 2 mg/ mL) supplemented with CHIR99201 (2 mM, Axon), noggin (100 ng/ mL, R&D systems), LDN (0.5 mM,
Axon), LM4A22 (2 ng/ mL, R&D system), GDNF (2 ng/ mL, R&D system), NT3 (10 ng/ mL, R&D Systems) and db-cAMP (0.5 mM,
Sigma). For immunocytochemistry with mouse anti-MAP2 antibodies (1:500, Sigma), hiNs were fixed in PFA (4%, 15 min at room
temperature) 7, 12 and 23 days after transgene activation. Neuronal conversion efficiency was assessed by quantification of
DAPI+/ MAP2+ hiNs using Cellomics Array Scan (Array Scan VTI, Thermo Fischer). Using the program ‘‘Target activation,’’ 20 fields
(10xmagnification) were automatically captured in a spiral fashion (from center to outside) and conversion efficiency was determined
as the ratio of total number of hiNs present at time of analysis and the number of input fibroblasts.
For RNA analysis, hiNs were detached using Accutase at days 12 and 23 after transgene expression and after gentle trituration,
filtered through cell strainer caps in order to obtain a single cell suspension. Cells were spun down and resuspended in the staining
buffer (HBSS supplemented with 45% BSA) for blocking (15 min at room temperature) before staining with hNCAM-APC antibody
(1:50) for 15 minutes at room temperature. A final centrifugation step and resuspension in HBSS 45% BSA, supplemented with
the secondary antibody, Nuclear Orange (ATT Bioquest) and DNase, were perfomed and viable, NCAM+ cells were isolated by
flow cytometry for RNA-seq library preparation.
For electrophysiological recordings, hFL1s were converted to iN on glass coverslips. Total 3 coverslips each on 3 different days,
from 2 independent cell conversion experiments were used. Patch-clamp electrophysiology was performed on hiNs at day 23-25
post-conversion. Cultured hiNs were grown on coverslips and transferred to a recording chamber and submerged in a continuously
flowing Krebs solution gassed with 95%O2 - 5%CO2 at 28
C. The composition of the standard solution was: 119 mMNaCl, 2.5 mM
KCl, 1.3 mMMgSO4, 2.5 mM CaCl2, 25 mMGlucose and 26 mM NaHCO3. Recordings were made with a Multiclamp 700B amplifier
(Molecular Devices), using borosilicate glass pipettes (3–7 MOhm) filled with the following intracellular solution: 122.5 mM potassium
gluconate, 12.5mMKCl, 0.2mMEGTA, 10mMHEPES, 2mMMgATP, 0.3mMNa3GTP and 8mMNaCl adjusted to pH 7.3 with KOH.
Data were acquired with pClamp 10.2 (Molecular Devices); current was filtered at 0.1 kHz and digitized at 2 kHz. Cells with neuronal
morphology with round cell body were selected for whole-cell patch clamp. Resting membrane potentials were monitored immedi-
ately after breaking-in in current-clampmode. Thereafter, cells were kept at amembrane potential of60mV to80mV, and 500ms
currents were injected from 20 pA to +90 pA with 10 pA increments to induce action potentials. For sodium and potassium current
measurements cells were clamped at 70mV and voltage-depolarizing steps were delivered for 100 ms at 10 mV increments.
Western Blotting
For pSmad3 blots, to confirm TGF-b inhibitors performed as expected, cells were serum starved for 1 hour in GMEM then placed in
fibroblast media containing 10 ng/ml TGF-b (R&D Systems) with or without TGF-b inhibitors, then western blotting was performed as
for all experiments, as follows. Cells were harvested in Trypsin-EDTA, lysed with 1x Nupage LDS lysis buffer (Life Technologies), with
or without phosphatase inhibitors (HALT, Life Technologies), heated to 95C for 10 minutes followed by sonication of 3 cycles of 15 s
on the Misonix XL2000 sonicator on setting 2. Protein concentration was measured by BCA assay (Life Technologies), and 1-100 mg
lysate was mixed with DTT (final 100 mM), then run at 150 V and transferred at 50 V for 3-hours with BioRad Mini-PROTEAN and Mini
Trans-Blot Cell tanks respectively. Antibodies used included pSMAD2/3 antibody (Santa Cruz sc-11769), and B-ACTIN-HRP anti-
body (Abcam, ab20272l).
Plasmids
For Smad2CA/3CA expression constructs, PCR primers were designed to amplify Smad2, Smad3 cDNA with base pair mismatches
at the 30 end, to exchange serine codons for glutamic acid (SSMS/SEME) inSmad2 or aspartic acid (SSVS/DDVD) inSmad3 in the
C terminus of the proteins (Chipuk et al., 2002; Funaba and Mathews, 2000). The primers used for mouse Smad2CA were forward-
CTAGGGTAGATTTACCGGGC, Reverse-CGAGTCTTTGATGGGTTTACTCCATCTCTGAGCATCGCACTGAA, and for Smad3CA
forward- GCTGGCGCCGGAACCAATTCAGTCGACGTGACCCTTCGGTGCCAG, reverse-CTAATCCACATCGTCACAGCGGATGCT
CGGGGAACCCATCTGGGT. The PCR products were then cloned into the TOPO Blunt vector and subsequently cloned into
pMXs or FUW expression vectors. A control vector pMXs-BFP was generated by inserting EBFP2 cDNA in the pMXs-gw (Addgene
#18656). pCXLE-hSmad2CA and pCXLE- hSmad3CA were generated by inserting human Smad2CA and Smad3CA coding
sequence into pCXLE-gw (Addgene #37626). Other pCXLE vectors were obtained from Addgene (Okita et al., 2011). The Cebpb
expression vector has been described previously (Di Stefano et al., 2014). The PRDM16 expression vector was kindly provided
byDr Kajimura (Kajimura et al., 2009). The lentiviral vectors used for hiN generation were described before (Pang et al., 2011; Pfisterer
et al., 2011; Vierbuchen et al., 2010). Plasmids used in this work are listed in the Key Resource Table.
Fluorescence activated cell sorting
Preparation of cells for sorting was performed in PBSwith 2%FCS at 4C. The following antibodies were usedwith indicated dilution:
ICAM1-biotin conjugate (1:100, eBioscience, #13-0541), CD44-allophycocyanin (APC) conjugate (1:300, eBioscience, #17-0441),
E-CADHERIN-eFluor 660 (1:300, eBioscience, #50-3249-82), MEFSK4-biotin conjugate (1:100, Miltenyi, 130-101-875), CD47-biotin
conjugate (1:100, BioLegend, 127505), CD73-Alexa Fluor 647 (1:300, BD Biosciences, 561543) and CD104-APC (1:300, Miltenyi,
130-106-924) and Strepdavidin PE-Cy7 (1:1500, eBioscience, #25-4317).Cell Stem Cell 21, 1–15.e1–e9, December 7, 2017 e4
Please cite this article in press as: Ruetz et al., Constitutively Active SMAD2/3 Are Broad-Scope Potentiators of Transcription-Factor-Mediated Cellular
Reprogramming, Cell Stem Cell (2017), https://doi.org/10.1016/j.stem.2017.10.013Immunofluorescence microscopy
Cells were reprogrammed in 6-well plates on 18mmcircular coverslips (Fisher Scientific) for confocal imaging, or directly on the plas-
tic for whole well imaging, both coated with gelatin. Cells were fixed with 4% Paraformaldehyde for 10 minutes, permeabilized in
0.1% Triton-X in PBS for 45 minutes, blocked in 5% normal goat serum in PBS for 1 hour at room temperature, and then stained
in blocking solution with primary antibody overnight at 4C. The next day, secondary antibody was applied in blocking solution
for 1 hour at room temperature. Slides where then mounted with prolong gold with or without DAPI (Life technologies). The following
antibodies were used with indicated dilution: p19ARF (1:300, Abcam, Ab80), E-CADHERIN-eFluor 660 (1:300, eBioscience,
#50-3249-82), CD44-allophycocyanin (APC) conjugate (1:300, eBioscience, #17-0441), pSmad3 (1:100, Cell Signaling, C25A9).
For confocal microscopy, all imaging was performed with a Leica TSC SP2 and processed using Adobe Photoshop. For whole
well colony and cell counting, the sistchedwhole well imageswere taken and analyzed using theCeligoSCell Cytometer (Nexcelom).
Smad2/3 double KO MEF reprogramming
An EF1a promoter-drivenCas9 expression cassette was targeted into theRosa26 locus of TNGMKOSES cell line, which has a doxy-
cycline (dox)-inducibleMKOS-ires-mOrange reprogramming and a CAG promoter-driven rtTA expression cassette in the Sp3 locus
and a Nanog-GFP reporter (Chantzoura et al., 2015). The resulting Cas9 TNG MKOS ES cells were used to generate chimeric em-
bryos via morula aggregation. Each E12.5 embryo was dissociated with trypsin/EDTA and 1/20 and 19/20 of the cells were seeded
in one well of a 12-well plate in the presence of dox and a 10 cm dish in the absence of dox, respectively. Two days later, the cells in
the 12-well plate were used to determine contribution of the Tg cell by measuring percentage of mOrange+ cells with flow cytometry.
MEFs with high (> 90%) Tg cell contribution were harvested from the 10 cm dishes, pooled and cryopreserved at 5x106 cells/vial as
passage 0. Lentiviral gRNA expression vectors were constructed by inserting double strand oligos encoding the following gRNA
sequencing into pKLV-U6gRNA(BbsI)-PGKpuro2ABFP. Defrosted cells were seeded into a T25 flask/vial (passage 1) and became
confluent within 2 days. The MEFs were harvested and seeded into a 6-well plate at 150,000 cells/well to make samples for western
blotting. A portion of remaining MEFs were mixed with wild-type (WT) MEFs (129 strain) as the percentage of the Tg MEFs became
5%, and the same amount (150,000 cells/well) of the mixed MEFs were seeded in a 6 well plate for reprogramming experiments
(passage 2). 24 hours later, cells for both experiments were infected with the same amount of gRNA viruses (MOI3) for 4 hours.
For western blotting, cells were harvested 72 hours after infection, and 3 mg of cell lysate was used to detect SMAD2/3 (1:1000,
Cell Signaling, #5678) and b-ACTIN (1:2500, Abcam, #ab20272). For reprogramming, dox was administrated 24 hours infection,
and number of Nanog-GFP+ colonies was assessed on day 14 of reprogramming. gRNA sequences are in Table S3.
Retroviral mediated gene transduction for iPSC reprogramming enhancement
Tenmicrograms of pMXs retroviral vector withBFP, dsRed (Addgene, 22724) (Hong et al., 2009),Smad2CA orSmad3CA, were trans-
fected into 1.7x106 Plat-E packaging cells in a 10 cm dish (Morita et al., 2000), in 8 mL of ESmedia, using the CaCl2-HBS transfection
method. The cells were cultured for 24 hours at 32C, and the viral supernatant was collected. Filtrated supernatant with 0.45 mm
Whatman acetate filters was thenmixed with 8 mg/ml polybrene, of which 2 mL was added to each well containing 1x105 MEFs. After
6-hours of infection at 32C, media was changed to initiate reprogramming and cells were placed back at 37C.
Human fibroblast reprogramming to iPSCs
Commercially available neonatal human dermal fibroblasts (nHDFs, Life technologies) were cultured as per manufacturer’s instruc-
tions. Reprogramming was accomplished by transfection of episomal plasmids as previously published (Okita et al., 2011). Briefly
5x105 passage 4 nHDFs were nucleofected (Amaxa, Human Dermal Fibroblast Nucleofector Kit, program U023) with 5 mg total
plasmids containing equal amounts pCXLE-hOct3/4-shp53 with pCXLE-hSK and pCXLE-hUL, +/ pCXLE-Smad3CA or pCXLE-
Smad2CA. After 5 days of expansion in nHDF media, cells were lifted with EDTA and 1.9x105 were plated on matrigel coated plates,
media was then changed 2 days later to E8 media (Life Technologies) supplemented with pen/strep (100 U/ml) and exchanged every
2 days until cells reached70%confluence, at which pointmedia was changed daily. Number of NANOG+ colonies was assessed on
day 21 of reprogramming immunofluorescence with anti-human NANOG antibody (1:200, BD PharMingen, #560482).
RNA-sequencing and data analysis
RNA-seq was performed with the single-cell tagged reverse transcription (STRT) platform using 500 cells/sample, which had been
snap frozen in PBS with RNase inhibitor, then processed as previously described (Islam et al., 2012; Islam et al., 2014). The RNA-seq
reads were processed by an automated pipeline as outlined in a recent publication (Islam et al., 2014). Counts data, based on both
read andmolecule counts, were processed with the DESeq2 (Version 1.6.3) package of Bioconductor(Love et al., 2014). However we
found that the processing steps used to produce molecule count data lead to the loss of read counts for low-abundance genes, so
proceeded with analysis on read count data, analogous to standard RNA-seq. 2-3 technical replicates per sample tightly clustered
and therefore summed across columns prior to further data processing. As per the standard DESeq2 protocol, normalized expres-
sion estimates were obtained by adjusting columns by a size factor corresponding to library size. For read counts, for example, this
adjustment ranged from 0.57 to 0.71. Data were transformed to log2 scale by use of DESeq20s rlog() command, which alsominimizes
differences at very low count levels. The clustering patterns of genes in the two series were assessed based on amatrix of themean of
biological replicate samples. Two matrices were constructed containing the Cont and +SmCA3 series. The mean of MEF and ES
samples were included in both series. To reduce noise, geneswith background level expression (nomean count > = 2) or low variatione5 Cell Stem Cell 21, 1–15.e1–e9, December 7, 2017
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Co-immunoprecipitation
Cells were suspended in hypotonic solution (10 mM HEPES pH7.9, 1.5 mM MgCl2, 10 mM KCl) containing proteinase inhibitors
(cOmplete protease inhibitor cocktail, Roche) and phosphatase inhibitors (HALT, Life Technologies) with 0.5%NP40, briefly vortexed
and left on ice for 5 minutes prior to centrifugation at 500 g to pellet nuclei. The pellet was suspended in high salt solution (HEPES
pH 7.9, 1.5 mM MgCl2, 0.2 mM EDTA, 400 mM NaCl, 25% Glycerol) to extract nuclear protein. The corrected nuclear lysates were
pre-cleared in IP-buffer (20 mM HEPES, 1.5 mM MgCl2, 0.2 mM EDTA, 20% Glycerol, 100mM NaCl, protease and phosphates
inhibitors) overnight at 4C with 25 mL Dynabeads-Protein G (Life Technologies, #10003D) that were pre-blocked blocked in 2%
milk with no-salt buffer (20 mM HEPES pH 7.9, 1.5 mMMgCl2, 0.2 mM EDTA, 20% Glycerol, phosphatase and protease inhibitors).
Bead-antibody complexes were generated by incubating 2 mg of antibody or control IgG with 25 mL blocked beads in IP buffer
rotating overnight at 4C. Antibody bound beads were then magnetically isolated and added to 200 mg pre-cleared lysate for a
3-hour incubation, rotating at 4C. Bead-protein complexes were then washed 3 times in IP buffer and processed for western in
LDS buffer as describe above. Antibodies used for co-IP experiments included Rb-SMAD3 (Abcam, #ab28379), ms-SMAD3 (Abcam,
#AF9F7), OCT4 (Santa Cruz Biotechnology, #sc8628), SOX2 (Santa Cruz Biotechnology, #sc17320), KLF4 (Santa Cruz Biotech-
nology, #sc20691), DPY30 (Sant Cruz Biotechnology, #sc167677), p300 (Thermo Scientific, #MS-586-PO), BRG1 (Santa Cruz
Biotechnology, #sc17796), MED15 (Sigma Aldrich, SAB2500761), and IgG (Millipore).
Chromatin Immunoprecipitation followed by high-throughput DNA sequencing (ChIP-seq)
Fixation
Cells were grown to 80% confluency and fixed by addition of formaldehyde (final 1%) for 12 minutes with gentle shaking at room
temperature. Formaldehyde was quenched with glycine (final 0.125 M) for 5 minutes shaking at room temp. Samples where then
washed once with cold PBS containing protease inhibitors (cOmplete protease inhibitor cocktail, Roche) collected with silicon
scrapers and centrifuged at 300 g for 5 minutes. Cells were re-suspended in PBS with protease inhibitor, and 2x106 cells (based
on sacrificed plate cell counts) were aliquoted into 1.5 mL tubes, centrifuged at 500 g and pellets were snap frozen on dry ice.
Nuclear isolation and sonication
A pellet of 2x106 cells was thawed and nuclei were isolated by re-suspension in lysis buffer (5 mM Pipes pH 8.0, 85 mM KCl, 1%
NP40) with fresh protease inhibitors (cOmplete protease inhibitor cocktail, Roche) for 20 minutes on ice followed by brief vortexing
and centrifugation at 500 g for 10minutes at 4C. The nuclear pellet was re-suspended in 300 ul IP buffer (0.5%SDS, 1%Triton, 2mM
EDTA, 20 mM Tris-HCl pH 8.0, 150 mM NaCl, fresh protease inhibitors) and sonicated to produce 200-300 bp fragments in a
BioRuptor Sonicator with a total of 5-8 cycles of: 10 pulses of sonication on the ‘‘high’’ setting, each followed by 30 s off. Thus,
each sample received between 50-80 pulses of 30 s ‘high’ sonication. Samples were then diluted in IP buffer without SDS (to final
0.1% SDS), then 8 mg antibody was added for overnight incubation, rotating at 4C.
Immunoprecipitation and DNA isolation
Dynabeads-ProteinG were blocked for 1-hour in 0.5%BSA in IP buffer with protease inhibitors, prior to incubation with the sonicated
antibody bound chromatin suspensions for 4-hours rotating at 4C. Bead-chromatin complexes were then serially washed for
5 minutes each with the following solutions: IP buffer (150 mM NaCl), followed by IP buffer with high salt concentration (500 mM
NaCl), then 1 wash with washing-buffer (10 mM Tris-HCl pH 8.0, 0.25 M LiCl, 0.5% NP40, 0.5% Na-Deoxycholate, 1 mM EDTA), fol-
lowed by 2 washes with TE (10 mM Tris, 1 mM EDTA). The DNA-protein complex was then eluted from beads by incubation with
100 ml of elution buffer (1% SDS, 10 mM EDTA, 50 mM Tris-HCl pH 8.0) for 30 minutes at 65C, vortexing every 10 minutes, followed
bymagnet extraction of beads. The beadswere re-washedwith 150 ml TE with 1%SDS,magnet extracted, and the TEwith remaining
DNA solution was added to the eluted samples, followed by 65C overnight incubation to reverse crosslink the DNA-protein com-
plexes. The dissociated DNA and protein solution was then treated with 4 units proteinase K (NEB) at 37C for 2 hours. DNA was
isolated with SeraMag beads, using 450 ml SeraMag bead solution and 225 ml of 30% PEG in 1.25 M NaCl (Sera-Mag DNA isolation
methods below) (Rohland and Reich, 2012). After bead purification, DNA was re-suspended in 30 ml DNase and RNase free H2O and
stored at 80C prior to library preparation.
ChIP library preparation for sequencing
Blunt end repair
The ChIP’d DNA from 2x106 cells, 6 ng total on average, was prepared in the following reaction mix: 5 ml T4 DNA ligase buffer
(NEB), 2 mL 10mMdNTP’s, 0.5 ml end repair mix (0.72 U T4 DNA polymerase, 0.24 U Klenow Fragment, 2.4 U T4 DNA Polynucleotide
Kinase), up to 50 ml with ddH2O (DNase/RNase free). Samples were incubated for 30minutes at 20C, and then purified with additionCell Stem Cell 21, 1–15.e1–e9, December 7, 2017 e6
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Adding A bases to 30 end of DNA fragment
The 16.5 ml blunt end repaired DNA fragments were mixed in the following reaction: 2 ml 10X NEB Buffer 2, 1 ml 4 mM dATP, 0.5 ml
Klenow 30 to 50 exonuclease minus (NEB). Reaction was incubated at 37C for 30 minutes.
Adaptor ligation
The 20 ml A-tailed DNAwas added to the following mix: 25 ml Quick Ligase Buffer, 1 ml Annealed TruSeq Adaptors (note below), 1.5 ml
Quick Ligase (2,000 U/ml NEB) 2.5 ml H2O. The reaction was incubated 20 minutes at room temperature and then 5 ml of 0.5 M EDTA,
pH 8.0. The adaptor ligated DNA fragments were then purified with addition of 50 ml SeraMag beadmix and 50 ml 30%PEG (in 1.25M
NaCl) as per bead protocol below. The final bead:DNA mixture was re-suspended in 15.5 ml TE, and 14 ml was taken to a new tube.
TruSeq adaptor annealing was performed by re-suspending adaptors at 100 mM (in 10 mM Tris-HCl pH7.8, 0.1 mM EDTA pH 8.0,
50 mM NaCl), mixing 1:1 with the universal adaptor (100 mM), and annealed using a program of: 2 min at 95C, 70 cycles of 30 s
(95C decreasing by 1C each cycle), hold at 4C. Annealed adaptors were diluted 1:200 (0.25 mM final) and then used for ligation
or stored at 20C and used for up to 5 freeze/thaw cycles.
Library pre-amplification
The adaptor ligated DNAwas amplified using the following protocol: 14 ml Adaptor-ligated DNA, 1 ml TruSeq primer cocktail (0.25 mM),
15 ml 2X Kapa HiFi HotStart readymix. The Libraries were amplified with the following protocol: 45 s at 98C, 5 cycles of (15 s at 98C,
30 s at 63C, 30 s at 72C), 1 minute of 72C, hold at 4C.
Library size selection
After pre-amplification of the library, a size selection step was performed to eliminate free adaptors in solution, and ensure amplifi-
cation of only the desired size ChIP DNA fragments (300-500bp). First, the volume of DNA solution from pre-amplification step was
adjusted to have 50 ml total (added 20 ul ddH2O). Then, 0.9X (45 ml) beads were added. After 15 minute incubation and 10 minutes
magnet extraction, the supernatant (92 ml) was transferred to new tube and beads discarded (containing fragments over 500 bp).
Then 10ml beads (0.2X) were added to the solution, incubated 15minutes followed by 10minutemagnet extraction of beads, 2 times
80% EtOH washes, and re-suspension in 11.5 ml TE. Then 10 ml pre-amplified and size selected DNA was transferred to a new tube.
From the final library, 1 ml was used to identify the number of additional cycles required, and then the remaining 9 ml were amplified an
additional 11-13 cycles as required. The final library was amplified as follows: 9 ml DNA, 1 ml TruSeq primer cocktail, 20 ml 2X Kapa
HiFi HotStart readymix, and 10 ml H2O. The library was amplifiedwith a program of 45 s at 98
C, 11-13 cycles of (15 s 98C, 30 s 63C,
30 s 72C), 1-minute 72C, hold at 4C. Therefore, each library was amplified a total of 16-18 PCR cycles. After amplification, the DNA
was isolated by bead purification by adding 60 ml SeraMag beads following described protocol below. Libraries were mixed at equal
concentration and sequenced with Edinburgh Genomics on the Illumina HiSeq 2500 platform.
Determining ChIP final library amplification cycle number required
We took 1 ml of pre-amplified, size-selected DNA, and performed a quantitative PCR reaction as follows: 1 ml library, 2 ml SybrGreen
fluorophore (10X), 1 ml TruSeq PCR primer cocktail, 10 ml 2X Kapa HiFi HotStart ready mix, split into 2 wells for qPCR analysis on a
lightcycler 480. Amplification conditions were: 3 minutes at 95C, 20 cycles of (30 s at 95C, 30 s at 63C, 30 s at 72C). Upon iden-
tifying the cycle number required to reach 50% amplification, we subtracted 2 from that number (based on optimization experience),
and used that as the number of cycles required for the rest of the library.
SeraMag bead isolation of DNA from solution
We produce SeraMag beads solution for DNA extraction in house, based on (Rohland and Reich, 2012). The final bead solution is
as follows: 0.1% SeraMag Magnetic Speed-beads (FisherSci, cat.#: 09-981-123), 18% PEG-800 (w/v) (Sigma Aldrich cat.#:
89510), 1MNaCl, 10mMTris-HCl pH 8.0, 1mMEDTA, 0.05% Tween 20. The beads are stored at 4C, and their efficiency was tested
using the Fermentas ladder (Fisher #FERSM1211).
For DNA isolation, the concentration of PEG can be adjusted by adding different volumes of the above SeraMag bead solution to
DNA, creating different stringency criteria for DNA-bead interaction, allowing for size selection of DNA fragments (Rohland andReich,
2012). For example, adding the SeraMag bead solution to a DNA containing solution at 1.2X (ie. 60 ml SeraMag bead mix to 50 ml
DNA), for a final concentration of 9.8% PEG, only DNA fragments greater than 100 bp in size bind to the beads. Increasing the ratio
of beads to DNA solution (resulting in increased PEG concentration) results in smaller sized fragments binding the beads.
The general protocol for beadmediated DNApurification is to add the SeraMag bead solution directly to theDNA solution, mixwell,
and let stand for 15 minutes. Then the DNA bound beads are magnet extracted for 5-10 minutes (depending on PEG concentration),
at which point the PEG solution is removed leaving 5 ml in bottom of tube so as not to lose any sample, prior to 2 washes with 80%
EtOH with tubes on magnet, air-dried for 2 minutes, and then re-suspended in TE (10 mM Tris-HCl pH 8.0, 0.1 mM EDTA) at desired
final volume plus 1.5 ml. After 2-minute incubation, the DNA solution is transferred to a new tube, leaving 1.5 ml remaining so as not to
take any beads.
ChIP-seq data analyses
Reads were quality-checked using FastQC and trimmed using Trimmomatic to remove adapters and low quality bases (Bolger et al.,
2014). Readswere aligned to themm10 assembly of themouse genome using Bowtie 2with the very-sensitive option (Langmead and
Salzberg, 2012). Duplicate reads were removed using Picard Tool’s MarkDuplicates command and were filtered for MAPQ > = 40e7 Cell Stem Cell 21, 1–15.e1–e9, December 7, 2017
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Peaks were called using MACS 2 on both individual and merged sample replicates against merged control replicates (Zhang et al.,
2008). For narrow peak factors, such as OCT4, peaks were called with the -q 0.01 and —call-summits specified. For broad peak
factors, such as SMAD3, peaks were called with the–broad and–broad-cutoff 0.1 options specified. Differentially-bound sites
were identified using the DiffBind software package from the Bioconductor project (Ross-Innes et al., 2012). A FDR% 0.1 and ab-
solute FC > = 1 were used as the significance threshold. Merged control replicates were used for contrast against each individual
sample replicate. The deepTools suite was used to generate normalized input-subtracted read coverage and heatmap scores using
the bamCompare and plotHeatmap commands, respectively. Normalized input-subtracted read coverage was generated from
merged sample and control replicates with the–ratio subtract and–normalizeTo1x 2150570000 option specified. Heatmaps were
generated using the normalized input-subtracted read coverage and peaks called from the merged sample replicates.
ATAC-seq
ATAC-seq was performed according to the published protocol (Buenrostro et al., 2013). For library preparation, 50,000 cells were
flow-sorted into PBS, and then nuclei were isolated by re-suspending the cells in lysis buffer (10 mM Tris-HCl pH 7.4, 10 mM
NaCl, 3 mM MgCl2, 0.1% NP-40) for 15 minutes on ice, followed by centrifugation at 500 g for 10 minutes at 4
C. Supernatant
was removed and nuclei were tagmented by re-suspension in the Nextera transposase mix (22.5 mL ddH2O, 25 mL 2x Tagment
DNA buffer, 2.5 ml Tagment DNA enyme) (Nextera DNA sample prep kit, FC-121-1030 and FC-121-1011) and incubated at 37C
for 30 minutes. The tagmentation reactions were terminated and cleaned-up using QIAGEN Minelute enzyme cleanup kit, eluting
in a final volume of 10 mL ddH2O. After tagmentation and cleanup, the DNA was then PCR amplified using Nextera primers, indexes
and polymerase mix according to the Nextera DNA sample prep kit protocol. The number of PCR cycles required was determined as
follows: the full library was amplified for five cycles, after which a 3 ml aliquot of the 30ul PCR reaction was removed and added to 6 ml
of the complete PCR cocktail with addition of 1 mL SybrGreen fluorophore (10,000x). The PCRoptimization reaction was run for 20 cy-
cles on the LightCycler480 instrument (same program as master library) to determine the additional number of cycles needed for the
remaining 27 mL reactions. The final cycle number was chosen to ensure the PCR was in linear phase growth and had not hit the
plateau phase, thus minimizing PCR biases. On average, libraries were produced with16 PCR cycles total. To the final 30 ml ampli-
fied library, 20 ml ddH2O was added prior to SeraMag bead cleanup. A ratio of 1.2X Bead:PCR reaction was used to isolate library
fragments larger than 100 bp, thus leaving the PCRprimers/adaptors out of the final solution sent for sequencing. ATAC libraries were
sequenced with Edinburgh Genomics on the Illumina HiSeq 2500 platform.
ATAC-seq data analysis
Reads were quality-checked using FastQC and trimmed using Trimmomatic to remove adapters and low quality bases (Bolger
et al., 2014). Reads were aligned to the mm10 assembly of the mouse genome using Bowtie 2 (Langmead and Salzberg, 2012)
with the–very-sensitive and -X 2000 options specified. Duplicate reads were removed using Picard Tool’s MarkDuplicates command
and were filtered using SAMtools for MAPQ > = 30 and the properly-paired (0x2) flag (Li et al., 2009). Reads aligned to the ENCODE
blacklist and mitochondrial blacklist regions were also removed using BEDTools (Quinlan and Hall, 2010). The deepTools suite was
used to generate normalized read coverage and heatmap scores using the bamCoverage and plotHeatmap commands, respectively
(Ramı´rez et al., 2014). Normalized read coverage was generated from merged sample replicates with the–normalizeTo1x
2150570000 option specified. Heatmaps were generated using the normalized read coverage and peaks called from the merged
sample replicates. The data of one of the ATAC-seq replicates had low read counts and demonstrated abnormal features as
assessed by PCA and hierarchical clustering, clustering independent of all other samples including the starting MEF population
and resulting iPSC cells, and was therefore removed from the analysis.
ChIP-qPCR for reprogramming to iPSCs
TheChIPedDNAwas treatedwith 2 mLRNase (Life Technologies) at 37C for 20minutes, and then stored at20C. EachChIP-qPCR
reaction used 0.25-0.5 mL of DNA suspension per reaction. The qPCRwas normalized to regions upstream ofOct4 andNanog,which
are devoid of SMAD3 or OCT4 binding based on previously published works (Chen et al., 2008; Mullen et al., 2011). Primers are listed
in Table S3.
qPCR in B cell to macrophage transdifferentiation
Total RNA was isolated using RNeasyMini Kit (QIAGEN) according to manufacture’s instruction. Double strand complementary DNA
(cDNA) was synthesized using the High Capacity RNA-to-cDNA kit (Applied Biosystems). Real-time Polymerase Chain Reaction
(PCR) was performed on ViiATM 7 system using Power SYBR Green PCR Master Mix (Applied Biosystems). The relative gene-
expression levels were calculated by 2DDCt method. Primers are listed in Table S3.
Bioinformatics analysis of B cell to macrophage transdifferentiation ChIP-seq data
All sequencing data were mapped onto the mouse genome assembly mm10 (Ensembl GRCm38.78) using STAR, then analyzed
with R (3.1.0) using packages from the bioconductor suite (v3.0). Cebpa ChIP-seq data were from GSE71218 (Di Stefano et al.,
2016) and GSE53362 (van Oevelen et al., 2015). Peak calling was performed using macs2 (2.1.0.20140616) with default parameters
and a threshold of qValue < 1e-2. Motif analyses were performed using sequences 500bp around Cebpa peak summits with RSATCell Stem Cell 21, 1–15.e1–e9, December 7, 2017 e8
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threshold of pValue < 1e-3 and the best hits for each peak were reported. We used as background a Marlov model of order1.
Gene ontology enrichments were analyzed using GREAT (McLean et al., 2010).
ChIP-qPCR with C10 pre-B cell line
C10 cells were cultured in PRMI medium (Life Technologies) complemented with 10% FBS (Life Technologies) and were induced to
transdifferentiate into macrophage (treatment with 100 nM b-estradiol and grown in medium in presence with 10 ng/mL of Il-3 and
CSF-1) as described (Bussmann et al., 2009). 18 hours after Cebpa expression vector infection, cells were cross-linked with 1%
formaldehyde for 10 minutes, and then lysed in ChIP buffer composed by mixing SDS buffer (NaCl 100 mM, Tris-Cl pH 8.1
50 mM, EDTA pH 8.0 5 mM, NaN3 0.2%, SDS 0.5%) and Triton Dilution Buffer (Tris-Cl pH 8.6 100 mM, NaCl 100 mM, EDTA
5 mM, NaN3 0.2% and Triton X-100 5%) at the ratio 2:1. Sonication was performed in a Bioruptor (Diagenode) and soluble material
containing fragmented chromatin was then incubated overnight with anti-Smad3 (Abcam, #ab28379) or IgG control antibodies
respectively. Immunoprecipitates were recovered with 60 mL of Dynabeads A or G (Life Technology) and washed 3 times with
low salt buffer (HEPES pH 7.5, 50 mM, NaCl 140 mM, Triton X-100 1%), once with high salt buffer (HEPES pH 7.5, 50 mM, NaCl
500mM, Triton X-100 1%) and decross-linked in freshly prepared elution buffer (1% SDS, NaHCO3 100mM and NaCl 500mM) over-
night at 65C on a shaker. Genomic DNA was eluted using PCR purification kit (QIAGEN). Primers are listed in Table S3.
QUANTIFICATION AND STATISTICAL ANALYSES
A one or two-sided t test was performed using the GraphPad Prism software for Figures 1, 2, 4, and 5. One-sided tests were chosen
for experiments where we expect unidirectional changes, such is for a ChIP-qPCR experiment, where enrichment is assessed for
binding a given chromatin region over unbound regions. P values represent * < 0.05; ** < 0.01; *** < 0.001. The number of experiments
and biological samples used is specified in figure legends. Error bars represent standard deviation.
DATA AND SOFTWARE AVAILABILITY
The accession number for the RNA-seq, ChIP-seq, and ATAC-seq data reported in this paper is GEO: GSE85178.e9 Cell Stem Cell 21, 1–15.e1–e9, December 7, 2017
